Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.

Authors
Gridelli, C
de Marinis, F
Thomas, M
Prabhash, K
El Kouri, C
Blackhall, Fiona H
Bustin, F
Pujol, J
John, W
San Antonio, B
Affiliation
Division of Medical Oncology, S. Giuseppe Moscati Hospital, Avellino, Italy
Issue Date
2014-07

Metadata
Show full item record
Abstract
The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous non-small-cell lung cancer. Approximately 17% of patients receiving maintenance therapy in this study were 70 years of age or older. Here we report efficacy and safety results from the PARAMOUNT study for elderly (≥70 years) and non-elderly (<70 years) patients.
Citation
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. 2014, 9 (7):991-7 J Thorac Oncol
Journal
Journal of Thoracic Oncology
URI
http://hdl.handle.net/10541/324254
DOI
10.1097/JTO.0000000000000207
PubMed ID
24926544
Type
Article
Language
en
ISSN
1556-1380
Collections